Transmission event of SARS-CoV-2 Delta variant reveals multiple vaccine breakthrough infections.

TitleTransmission event of SARS-CoV-2 Delta variant reveals multiple vaccine breakthrough infections.
Publication TypeJournal Article
Year of Publication2021
AuthorsFarinholt, T, Doddapaneni, H, Qin, X, Menon, V, Meng, Q, Metcalf, GA, Chao, H, Gingras, M-C, Farinholt, P, Agrawal, C, Muzny, DM, Piedra, PA, Gibbs, RA, Petrosino, J
Date Published2021 Jul 12

IMPORTANCE: Vaccine breakthrough by an emergent SARS-CoV-2 variant poses a great risk to global public health.

OBJECTIVE: To determine the SARS-CoV-2 variant responsible for 6 cases of vaccine breakthrough.

DESIGN: Nasopharyngeal swabs from suspected vaccine breakthrough cases were tested for SARS-CoV-2 by qPCR for Wuhan-Hu1 and Alpha variant. Positive samples were then sequenced by Swift Normalase Amplicon Panels to determine the causal variant.

SETTING: Transmission event occurred at events surrounding a wedding outside of Houston, TX. Two patients from India, likely transmitted the Delta variant to other guests.

PARTICIPANTS: Following a positive SARS-CoV-2 qPCR test at a third-party site, six fully vaccinated patients were investigated. Three males and three females ranged from 53 to 69 years old. One patient suffered from diabetes while three others were classified as overweight. No significant other comorbidities were identified. None of the patients had a history of failed vaccination.

KEY POINTS: Which SARS-CoV-2 variant is responsible for 6 cases of vaccine breakthrough, one interventional monoclonal antibody treatment, and one death? Viral sequencing revealed 6 vaccinated patients were infected with the Delta SARS-CoV-2 variant. With no histories of vaccine breakthrough, this suggests Delta variant may possess immune evasion in patients that received the Pfizer BNT162b2, Moderna mRNA-1273, and Covaxin BBV152. Delta variant may pose the highest risk out of any currently circulating SARS-CoV-2 variants, with increased transmissibility over Alpha variant and possible vaccine breakthrough.

Alternate JournalmedRxiv
PubMed ID34268529
PubMed Central IDPMC8282118
Grant ListU19 AI144297 / AI / NIAID NIH HHS / United States